AMICUS THERAPEUTICS INC (FOLD) Stock News
NASDAQ:FOLD - Nasdaq - US03152W1099 - Common Stock - Currency: USD
FOLD Latest News, Press Relases and Analysis
Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now?
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael Yee, […]
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
New Strong Buy Stocks for April 1st
AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney...
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase...
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: YMAB
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]
Amicus Therapeutics to Report Q1 Earnings: What's in the Cards?
On FOLD's first-quarter 2025 earnings call, investors are likely to focus on the sales of lead drug Galafold and the combo drug, Pombiliti + Opfolda.
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires?
We recently published a list of 10 Best Low Cost Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other best low cost stocks to buy according to billionaires. Markets are wobbling, and panic is becoming the headline. At times […]
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP...
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across...
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® ...
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief...
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh